Tevogen announced on March 5 2026 that it entered into a non‑exclusive, non‑binding letter of intent to evaluate a potential acquisition of Apozeal Pharmaceuticals, a company with 11 FDA‑approved ANDA products and a pipeline of additional filings.
The deal would add a revenue‑generating generics business to Tevogen’s precision T‑cell platform, addressing the company’s liquidity challenges and zero revenue growth over the past three years. Tevogen’s current financial profile includes negative earnings, a low current ratio, and a Z‑Score of 0, underscoring the urgency of new cash‑flow sources.
Tevogen’s reverse stock split, effective March 6, was undertaken to regain compliance with Nasdaq’s minimum bid price requirement. The company has pursued a $36 million line of credit and a $14 million contingent private placement, and has received grant funding for its AI initiatives, but the acquisition of Apozeal could provide the first substantial operating revenue stream.
Apozeal’s portfolio of 11 FDA‑approved generic products and its ongoing development of additional ANDAs position it as a ready‑to‑scale generics platform. The company recently invested $4.1 million to expand a manufacturing facility in Levittown, Pennsylvania, and aims to produce 100 % of its products domestically.
"Tevogen Generics was launched with the objective of supporting pharmaceutical affordability and domestic manufacturing in the United States. The potential acquisition of Apozeal represents a meaningful step toward that strategy. With FDA‑approved ANDA assets and a growing development pipeline, Apozeal could provide a foundation for building a revenue‑generating generics business and could support Tevogen's broader plan to expand U.S.-based pharmaceutical manufacturing," said Dr. Ryan Saadi, founder and CEO.
The letter of intent does not disclose a purchase price or definitive terms, and the transaction remains subject to due diligence, negotiation, and regulatory approvals. No financial terms have been made public, and the due‑diligence timeline has not been specified.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.